

2025 CGA-IGC Annual Meeting


The Collaborative
Group of the Americas
on Inherited
Gastrointestinal
Cancer

October 9-11, 2025
St. Louis



FINAL
PROGRAM
E-BOOK

TABLE OF CONTENTS




**2025 CGA-IGC
Annual Meeting**

October 9-11, 2025
St. Louis

WELCOME ADDRESS	3
FLOORPLAN	4
GENERAL INFORMATION	5
PROGRAM AT A GLANCE	8
SOCIAL ACTIVITIES	11
SCIENTIFIC PROGRAM	12
THURSDAY, OCTOBER 9, 2025	12
FRIDAY, OCTOBER 10, 2025	14
SATURDAY, OCTOBER 11, 2025	16
INVITED SPEAKERS	17
SPONSORS & EXHIBITORS	18
SPONSORED INDUSTRY SYMPOSIA	19
SPONSORS & EXHIBITORS DIRECTORY	21
ADVERTS	29
SAVE THE DATE – #CGAIGC26	33

WELCOME ADDRESS



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

Dear Colleagues and Friends,

I am excited to invite you to the CGA-IGC Annual Meeting in St. Louis, MO, from October 9-11, 2025. This year, we celebrate the 30th anniversary of the founding meeting of CGA-IGC, which was held in St. Louis in 1995.

Much has changed since 1995, but CGA-IGC remains an organization in which health care providers, scientists, and like-minded partners come together to improve the diagnosis, treatment, and care of individuals with hereditary gastrointestinal cancer predisposition syndromes.

As always, our meeting will feature unmatched scientific content including the latest innovations and breakthroughs in the clinical care of hereditary gastrointestinal cancer predisposition syndromes, which will be delivered by experts from around the world. This year, we also look forward to highlighting our organization's history and its role in shaping the field.

Whether you are a long-time member or a first-time attendee, I look forward to welcoming you to another outstanding CGA-IGC Annual Meeting.


On behalf of the CGA-IGC Meeting Planning Committee,



Beth Dudley Yurkovich, MS, MPH, CGC, CGAF


CGA-IGC President & Chair of the Meeting Planning Committee

FLOORPLAN



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis



Jscreen	1
ConnectMyVariant	2
Myriad Genetics	3
Natera	4
Invitae / Labcorp	5
Ambry Genetics	6
Tempus	7
Exact Sciences	8
Siteman Cancer Center	9
Lynch Syndrome Awareness	10
PanCAN	11

Dana Farber Cancer Institute	12
CGA-IGC	13
CCARE Lynch Syndrome	18
Jacqueline Rush Foundation	19
King Center for Lynch Syndrome at Penn Medicine's Abramson Cancer Center	20
Lynsight	21
AliveandKick'n	22
FightCRC	23
ClearNote Health	24
Caris Life Sciences	25

GENERAL INFORMATION



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

MEETING DATES | DESTINATION | VENUE | WEBSITE

October 9-11, 2025 | St. Louis, MO, USA |
Hyatt Regency St. Louis at The Arch

MEETING HOURS

Registration Desk Opening Hours

Thursday, October 9, 2025	06:30 – 18:00
Friday, October 10, 2025	06:30 – 18:00
Saturday, October 11, 2025	06:30 – 15:00

Daily Agenda Hours

Thursday, October 9, 2025	07:00 – 19:00
Friday, October 10, 2025	07:00 – 19:00
Saturday, October 11, 2025	07:00 – 16:00

Exhibition Opening Hours

Thursday, October 9, 2025	07:00 – 19:00
Friday, October 10, 2025	07:00 – 19:00
Saturday, October 11, 2025	07:00 – 15:00

PRACTICAL INFORMATION FOR THE MEETING

Time Zone

St. Louis, MO operates according to Central Standard Time (CST) in October, which is 6 hours behind Coordinated Universal Time (UTC-6).

Language of the Meeting

The official language of the 2025 CGA-IGC Annual Meeting is English. No translations will be available during the sessions.

Wi-Fi Network for Meeting Participants

We are pleased to offer complimentary Wi-Fi access to all CGA-IGC 2025 participants. Please check for the network name and password from the Wi-Fi signs in the meeting area.



Dress Code for Meeting Participants

The dress code for the 2025 CGA-IGC Annual Meeting is business formal or business casual for all occasions unless stated otherwise.

F&B

Coffee breaks as stated in the meeting scientific program will be served in the Exhibition Area.



In the meeting scientific program, there are 3 sponsored breakfast industry symposia (on Thursday, Friday and Saturday) and 2 sponsored lunch industry symposia (on Thursday and Friday). During these sponsored symposia, the sponsoring company will provide the F&B for the participants attending the session. The F&B stations for these meal services will be located inside the Industry Symposium Hall.



CME / CEU ACCREDITATION

For the 2025 CGA-IGC Annual Meeting, relevant applications have been made for CME and CEU accreditations for the attendees. For the accreditation process and claim of credits, the attendees will be required to fill in the Post-Meeting Survey and the Online Evaluation Form, which will be shared with all participants after the meeting.

CEU Accreditation for Genetic Counselors

The National Society of Genetic Counselors (NSGC) has authorized The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) to offer up to **2.733 CEUs** or **27.33 Category 1** contact hours for the activity 2025 CGAIGC Annual Meeting. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor recertification.

Genetic Counselor (GC) attendees of the meeting who have applied for CEU accreditation during the registration process can claim credits after filling in the Post-Meeting Survey and the Online Evaluation Form mentioned above.

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The Collaborative Group of the Americas on Inherited Gastrointestinal. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CME Accreditation for Physicians

The 2025 CGA-IGC Annual Meeting has been planned and implemented in accordance with the accreditation requirements and policies of the Postgraduate Institute for Medicine (PIM).

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity

GENERAL INFORMATION



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

for a maximum of estimated 19.25 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is estimated **19.25** contact hours.

American Board of Surgery (ABS) Continuous Certification Program

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. **19.25** ABS MOC

Canadian Board of Genetic Counselling CME - CBGC CEC

The 2025 CGA-IGC Annual Meeting has been approved by the Canadian Board of Genetic Counselling (CBGC) for **19.83** CECs.

INFORMATION FOR SPEAKERS & PRESENTERS

All invited speakers, oral abstract presenters, and industry session speakers will be able to preview and edit (if necessary) their slide sets at the Speaker Preview Corner in Liberty B. After previewing and editing the slides, you are kindly asked to deliver your presentation(s) to the technical desk in the main Plenary Session Hall (Liberty CD) at least 4 hours prior to the start time of your session(s). If the session is the first session in the morning, please upload your presentation the day before.

Speakers' Preview Corner Opening Hours:

Thursday, October 9, 2025	06:30 – 18:00
Friday, October 10, 2025	06:30 – 18:00
Saturday, October 11, 2025	06:30 – 15:00

MEETING MATERIALS FOR PARTICIPANTS

Name Badges & Mini Program

The name badges and the mini programs will be distributed from the Registration desk. All participants are kindly asked to wear their name badges throughout the Annual Meeting.

Meeting Bags & Inclusions

The Annual Meeting bags include notepads, pens, CGA-IGC, and industry bag inserts. They will be distributed from the Registration desk.

Certificates of Attendance

The certificates of attendance will be sent to all participants as a PDF file via e-mail after the Annual Meeting.

Certificates of Presentation

The presenters of oral and poster abstracts will be eligible to get a certificate of presentation, which will be sent to the presenters upon request after the Meeting. You may contact the Meeting Organizing Secretariat (Ms. Cagla Avcioglu at cavcioglu@kenes.com) to receive your presentation certificates.

Final Program E-Book & Abstracts' E-Book

A Final Program E-Book (PDF) including all relevant information about the Annual Meeting and the Abstracts' E-Book (PDF) giving our attendees access to the abstracts during the presentations, will be available for display and downloading on the mobile application of the Annual Meeting.

Official Abstracts Publication in Familial Cancer Journal

All presented abstracts of the 2025 CGA-IGC will be published online in the Familial Cancer Journal. The publication process will start after the Annual Meeting ends and when it is published all participants will be provided with the relevant URL to access the published journal.

Mobile Application

The Meeting mobile application is prepared for you to navigate through the Meeting details with ease and enhance your participation. You may download it through IOS/App Store or Android/Google Play via the QR codes below.



Download from
IOS/App Store



Download from
Android/Google Play

The event code for the mobile application is **CGAIGC25**. To log into the mobile app, please use the credentials that were sent to you via e-mail before the Meeting.

GENERAL INFORMATION



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

DISCLAIMER

Liability & Insurance

The CGA-IGC and the Meeting Organizing Secretariat cannot accept liability for personal accidents or loss of or damage to the private property of participants. Upon registration, participants agree that neither the CGA-IGC nor the Meeting Organizing Secretariat assumes any liability. Participants are advised to take out their own personal travel and health insurance for their trip.

Safety and Security

Bags and/or suitcases must not be left unattended at any time whether inside or outside the Meeting venue and session hall(s). As all hotels do, we strongly recommend our participants to use their safety deposit boxes for their valuables.

MEETING ORGANIZING SECRETARIAT



Office: Kenes M+

Registration, Accommodation & Travel Inquiries

Ms. Neyir Utugen, Registration & Accommodation Manager

E-mail: nutugen@kenes.com

Scientific Inquiries

Ms. Cagla Avcioglu, Scientific Program Coordinator

E-mail: cavcioglu@kenes.com

Sponsorship & Exhibition Inquiries

Mr. Daghan Sivaci, Industry Liaison & Sales Manager

E-mail: dsivaci@kenes.com

Promotional Inquiries

Ms. Gizem Unsalan, Senior Marketing Coordinator


E-mail: gunsalan@kenes.com

Any Other Inquiries

Ms. Lara Volkan, Project Manager

E-mail: lvolkan@kenes.com

PROGRAM AT A GLANCE




2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract Sessions
	Sponsored Symposium
<i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>	

THURSDAY, OCTOBER 9	
Time Slot	Plenary Hall - Regency ABC
07:00 - 07:45	Breakfast Symposium Sponsored by Exact Sciences
08:00 - 08:15	Welcome & Housekeeping <i>Beth Dudley Yurkovich, CGA-IGC President</i>
08:15 - 09:00	Session I: Named Lecture - James Church Lecture <i>Moderator: Matthew Kalady</i> A Short History of CGA-IGC, <i>James Church</i>
09:00 - 09:55	Session II: Debate <i>Moderator: Marianne Dubard-Gault</i> Is Bigger Really Better? Debating Genetic Test Panel Size, <i>Maegan Roberts & Dana Farengo-Clark</i>
09:55 - 10:15	AM Break
10:15 - 12:15	Session III: Advocacy <i>Moderators: Emma Keel & Gautam Mankaney</i>
12:15 - 13:30	LUNCH BREAK
12:20 - 13:20	Lunch Symposium Sponsored by Natera
13:30 - 15:00	Presidential Plenary I <i>Moderators: Bryson Katona & Beth Dudley Yurkovich</i>
15:00 - 15:40	PM Break
15:05 - 15:35	CCARE Lynch Poster Walk <i>Moderators: Timothy Yen & Yvonne Cardona</i>
15:40 - 17:00	Session IV: Oncology <i>Moderators: Mohammad Ali Abbas & Olivia Aranha</i>
17:00 - 18:00	Session V: Hereditary Live <i>Moderator: Joshua Sommovilla</i>
18:00 - 19:00	Poster Session I

PROGRAM AT A GLANCE



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract Sessions
	Sponsored Symposium
<i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>	

FRIDAY, OCTOBER 10	
Time Slot	Plenary Hall - Regency ABC
07:00 - 07:45	Breakfast Symposium Sponsored by Ambry Genetics
08:00 - 08:15	Welcome & Housekeeping <i>Beth Dudley Yurkovich, CGA-IGC President</i>
08:15 - 10:00	Session VI: Lynch Syndrome <i>Moderators: Chinedu Ukaegbu & Sheila Rustgi</i>
10:00 - 10:20	AM Break
10:20 - 11:05	Session VII: Named Lecture - Anne Krush Lecture <i>Moderator: Cathryn Koptiuch</i> Patient-focused Population Ascertainment for Automated Genetic Services, <i>Wendy Kohlmann</i>
11:05 - 12:15	Session VIII: Delivery of Care <i>Moderators: Lauren Gima & Jennifer Fijor</i>
12:15 - 13:30	LUNCH BREAK
12:20 - 13:20	Lunch Symposium Sponsored by Immunovia
13:30 - 15:00	Presidential Plenary II <i>Moderators: Beth Dudley Yurkovich & Elana Levinson</i>
15:00 - 15:20	PM Break
15:20 - 16:50	Session IX: Surveillance and Prevention <i>Moderators: Rachel Hodan & Dan Chung</i>
17:00 - 18:00	Session X: Jeopardy <i>Moderators: Mike Hall & Kimberly Hilfrank</i>
18:00 - 19:00	Poster Session II

PROGRAM AT A GLANCE




2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract Sessions
	Sponsored Symposium
<i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>	

SATURDAY, OCTOBER 11	
Time Slot	Plenary Hall - Regency ABC
07:00 - 07:45	Breakfast Symposium Sponsored by Biodexa Pharmaceuticals
08:00 - 08:15	Welcome & Housekeeping <i>Beth Dudley Yurkovich, CGA-IGC President</i>
08:15 - 09:00	Session XI: Named Lecture - Charis Eng Lecture Moderator: <i>Brandie Leach</i> What You Should Know About PTEN, <i>Joanne Ngeow</i>
09:00 - 10:30	Session XII: Upper GI Management Moderators: <i>Jennifer Weiss & Joshua Melson</i>
10:30 - 10:50	AM Break
10:50 - 12:15	Session XIII: Population Based Testing Moderators: <i>Julie Moskowitz & Heather Hampel</i>
12:15 - 13:30	LUNCH BREAK
13:30 - 15:00	Presidential Plenary III Moderators: <i>Elana Levinson & Gregory Idos</i>
15:00 - 16:00	CGA-IGC Business Meeting & Presidential Transition <i>Beth Dudley Yurkovich & Mike Hall & Bryson Katona</i> Post Meeting Wrap Up <i>Elana Levinson</i>

SOCIAL ACTIVITIES



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

COMMITTEE MEETINGS

Date : Wednesday, October 08, 2025
Time : 14:00 - 16:00
Location : 2nd Level – Regency Ballroom Level

Communication Committee Meeting	Sterling Studio 3
JEDI Committee Meeting	Sterling Studio 4
Membership Committee Meeting	Sterling Studio 6
Education Committee Meeting	Sterling Studio 7
Research Committee Meeting	Sterling Studio 8

SOCIAL ACTIVITIES

CGA-IGC Awards Reception


Date : Wednesday, October 08, 2025
Time : 16:00 - 18:30
Location : 18th Level - Gateway East

Invitation-only event is for attendees who have already RSVPed.

Gateway Gala with CGA-IGC & Fight CRC

Date : Thursday, October 9, 2025
Time : 19:30 - 23:30
Location : 18th Level - Gateway East

A separate ticket is required.



Supported by



CCARE Lynch Poster Walk

Supported by CCARE Lynch Syndrome
Date : Thursday, October 9, 2025
Time : 15:05 - 15:55
Location : Poster Area – Regency D



Poster Session 1

Supported by OSU/James Cancer Center
Date : Thursday, October 9, 2025
Time : 18:00 - 19:00
Location : Poster Area – Regency D

The James




Poster Session 2

Supported by OSU/James Cancer Center
Date : Friday, October 10, 2025
Time : 18:00 - 19:00
Location : Poster Area – Regency D

The James



SCIENTIFIC PROGRAM




2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract
	Sponsored Symposium <i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>

THURSDAY, OCTOBER 9	
Time Slot	Plenary Hall - Regency ABC
07:00 - 07:45	<p>Breakfast Symposium Sponsored by Exact Sciences: Cologuard and Colorectal Cancer Detection in Lynch Syndrome--An Introduction to the CORAL Study</p> <p>Moderator: Brandie Leach, MS, CGC</p> <p>Speaker: Bryson Katona, MD, PhD Jordan J. Karlitz, MD, FACP, AGAF</p>
08:00 - 08:15	<p>Welcome & Housekeeping <i>Beth Dudley Yurkovich, CGA-IGC President</i></p>
08:15 - 09:00	<p>Session I: James Church Lecture <i>Moderator: Matthew Kalady</i> Introduction, <i>Matthew Kalady</i> James Church Lecture: A Short History of CGA-IGC, <i>James Church</i> Q&A</p>
09:00 - 09:55	<p>Session II: Debate <i>Moderator: Marianne Dubard-Gault</i> Is Bigger Really Better? Debating Genetic Test Panel Size, <i>Maegan Roberts & Dana Farengo-Clark</i></p>
09:55 - 10:15	AM BREAK
10:15 - 12:15	<p>Session III: Advocacy <i>Moderators: Emma Keel & Gautam Mankaney</i> Addressing Financial Toxicity For Patients With Hereditary GI Syndromes, <i>Yvonne Bombard</i> Q&A Healthcare Policy Advocacy For Hereditary GI Syndromes, <i>Swati Patel</i> Q&A Genetic Counselor Advocacy: Creating A Seat At The Table, <i>Sara Pirzadeh-Miller</i> Q&A, Using Patient Advocacy To Fight For Change, <i>Ben White</i> Q&A</p>
12:15 - 13:30	LUNCH BREAK
12:20 - 13:20	<p>Lunch Symposium Sponsored by Natera: Bridging the Gap: Driving Hereditary Testing Uptake Using Integrated Somatic-germline InsightH</p> <p>Speaker: Abigail Ward, MS, CGC Asaf Maoz, MD</p>
13:30 - 15:00	<p>Presidential Plenary I <i>Moderators: Bryson Katona & Beth Dudley Yurkovich</i> RT-001 Financial Distress Among Young Adults With Early-Onset Gastrointestinal Cancers: A Call To Action, <i>Alessandro Mannucci</i> RT-002 Genetic Cancer Prevention Clinic: Clinical Outcomes Review, <i>Jacqueline Mersch</i> RT-003 MUTYH-Associated Polyposis In Adolescents: A Case Series, <i>Kristin Zolley</i> RT-004 Cigarette Smoking And Age Of Pancreatic Adenocarcinoma Diagnosis For Hereditary Pancreatic Cancer Patients, <i>Timothy Shu</i> RT-005 Repeat Gastric Body And Antrum Biopsies In Lynch Syndrome Yield Newly Identified Gastric Intestinal Metaplasia, <i>Jessica Vadaketh</i> O-001 Cancer Penetrance Among CTNNA1 Loss-Of-Function Carriers: Initial Cancer Risk Estimates From The CTNNA1 Familial Expansion (CAFÉ) Study, <i>Dana Farengo-Clark</i> O-002 DNA Mismatch Repair Deficiency And Clinical Features Of Prostate Cancer Among Lynch Syndrome Patients, <i>Linda Rodgers-Fouche</i> O-003 Spatially Resolved Transcriptomic Analysis Of Gastric Precancers Arising In Germline CDH1 Variant Carriers, <i>Jeremy Davis</i> O-004 Analysis Of Missense Variants In RPS20 And An Association With Colorectal Cancer Predisposition, <i>Jennifer Herrera-Mullar</i> O-005 Evaluating The Diagnostic Yield Of Updated Genetic Testing In Individuals With Idiopathic Adenomatous Polyposis, <i>Blake Rowell</i></p>



Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract
	Sponsored Symposium <i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>


THURSDAY, OCTOBER 9	
Time Slot	Plenary Hall - Regency ABC
15:00 - 15:40	PM BREAK
15:05 - 15:35	<p>CCARE Lynch Poster Walk Moderators: Timothy Yen & Yvonne Cardona P-052 A Retrospective Review of Associated Urothelial Malignancies Within a Lynch Syndrome Population, Anudeep Mukkamala P-047 Streamlined Care for Canadians with Mismatch Repair Deficient Cancers Through Full-Service Genetic and Epigenetic DNA Sequencing, Jaime Jessen P-060 Empowering Individuals at Risk for Lynch Syndrome: User-Driven Development of an Intervention Booklet for Cascade Genetic Services, Haoyang Yan P-054 Endometriosis And Ectopic Endometrial Cancer in Lynch Syndrome, Linda Rodgers-Fouche P-017 Measuring Preferences for Dietary Prevention Interventions Among Patients (Pts) With Lynch Syndrome (LS), Devang Namjoshi</p>
15:40 - 17:00	<p>Session IV: Oncology Moderators: Mo Abbas & Olivia Aranha Watch And Wait: Management Of Mismatch Repair Proficient Rectal Cancer, Rodrigo Oliva Perez Q&A Non-Operative Management Of Mismatch Repair Deficient Cancers, Zsofia Stadler Q&A How We Do It: DPYD variant testing prior to the use of fluoropyrimidine-based chemotherapy among GI cancer patients: An exploration of current approaches and opportunities for increased Genetic Counselor involvement, Madeline Smith & Daniel Hertz & Arravinth Anantharajah & Heather Glessner Q&A</p>
17:00 - 18:00	<p>Session V: Hereditary Live Moderator: Joshua Sommovilla Panelists: Lisen Axell & Luigi Ricciardiello & Maria McGreevy & David Liska</p>
18:00 - 19:00	Poster Session I



Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract
	Sponsored Symposium <i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>

FRIDAY, OCTOBER 10	
Time Slot	Plenary Hall - Regency ABC
07:00 - 07:45	<p>Breakfast Symposium Sponsored by Ambry Genetics: GI Classifi-ed: Our Comprehensive and Adaptive Approach to Genomic Results Interpretation</p> <p>Speakers: Holly LaDuca, MS, CGC Jeni Herrera-Mullar, MGC, LCGC, DMA Tina Pesaran, MA, MS, CGC</p>
08:00 - 08:15	<p>Welcome & Housekeeping <i>Beth Dudley Yurkovich, CGA-IGC President</i></p>
08:15 - 10:00	<p>Session VI: Lynch Syndrome <i>Moderators: Chinedu Ukaegbu & Sheila Rustgi</i> What's Different About Lynch-Associated Gynecologic Cancers?, <i>Ying Liu</i> Q&A Lynch Syndrome Network Consensus (Lynsync) International Guidelines, <i>Giulia Martina Cavestro</i> Q&A Capp3: An Update On Aspirin Chemoprevention In Lynch Syndrome, <i>John Burn</i> Q&A Emerging Treatments For Lynch-Related Cancers, <i>Asaf Maoz</i> Q&A</p>
10:00 - 10:20	AM BREAK
10:20 - 11:05	<p>Session VII: Anne Krush Lecture <i>Moderator: Cathryn Koptiuch</i> Introduction, <i>Cathryn Koptiuch</i> Anne Krush Lecture: Patient-focused Population Ascertainment for Automated Genetic Services, <i>Wendy Kohlmann</i> Q&A</p>
11:05 - 12:15	<p>Session VIII: Delivery of Care <i>Moderators: Lauren Gima & Jennifer Fijor</i> Genetics Service Delivery in a Safety Net Hospital: Lessons from Clinic and Research, <i>Charite Ricker</i> Q&A How We Do It: Leveraging Innovation to Improve Access to Hereditary Cancer Genetic Testing in an NP Led Clinic, <i>Ashley Hendershot & Carol Shaw & Patricia Mallaber</i> Q&A O-006 Integrating Genetic Social Work to Address Psychosocial Challenges in Hereditary Cancer Care, <i>Emily Epstein</i></p>
12:15 - 13:30	LUNCH BREAK
12:20 - 13:20	<p>Lunch Symposium Sponsored by Immunovia: Controversies in Pancreatic Cancer Surveillance Guidelines and the Potential Role for Blood Based Biomarker Testing</p> <p>Moderator: Jeff Borcharding</p> <p>Speaker: Bryson Katona, MD</p>

SCIENTIFIC PROGRAM




2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract
	Sponsored Symposium

**All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.*


FRIDAY, OCTOBER 10	
Time Slot	Plenary Hall - Regency ABC
13:30 - 15:00	<p>Presidential Plenary II Moderators: Beth Dudley Yurkovich & Elana Levinson</p> <p>RT-006 Evaluation Of An Employer-Based Cancer Benefit Program Facilitated By Genetic Counselors, Kelly Knickelbein</p> <p>RT-007 Assessment Of Reasons For Pancreatic Cancer Surveillance Cessation Or Deferral Amongst High-Risk Individuals, Grace Snyder</p> <p>RT-008 Expanding The Spectrum: Extra-Colonic Malignancies In MUTYH-Associated Polyposis, Lisa A Laguardia</p> <p>RT-009 Comparing And Contrasting Lived Experiences Of Patients With Lynch Syndrome And Polyposis Syndromes, John Krebsbach</p> <p>RT-010 The Longest Documented Follow-Up Of A Large Ampullary Adenoma In FAP: A 30-Year Cancer-Free Case, Youssef Soliman</p> <p>O-007 Post Operative Outcomes Of CDH1 Carriers Undergoing Gastrectomy– Results Form The GASTRIC Consortium, Ajay Bansal</p> <p>O-008 Real World Adherence To Colorectal Cancer Screening In Patients With MLH1 And MSH2 Lynch Syndrome At A Tertiary Community Cancer Center, Marianne Dubard-Gault</p> <p>O-009 Identifying Barriers To Hispanic/Latino Participation In Cancer Clinical Trials: A Pilot Study, Dimitros Varvoglis</p> <p>O-010 Who's In The Driver's Seat? Assessment Of Germline Drivers Of Early-Onset Endometrial Cancer, Juliet Milani</p> <p>RT-011 Rate And Root Cause Analysis Of Post-Colonoscopy Colorectal Cancer In Lynch Syndrome: The Potential Of The LINEAGE Consortium, Minh Do</p> <p>RT-012 Cancer Risk In Individuals With Hamartomatous Polyposis Syndromes: A Call For Collaboration, Bryson Katona</p> <p>RT-013 Perceptions Of Gastric Cancer Risk And Attitudes Towards Endoscopic Surveillance In Patients With CDH1 Pathogenic Variants, Conner Lombardi</p>
15:00 - 15:20	PM BREAK
15:20 - 16:50	<p>Session IX: Surveillance and Prevention Moderators: Rachel Hodan & Dan Chung</p> <p>Dermatologic Findings In Hereditary Gi Syndromes: Diagnosis And Surveillance, Ata Moshiri</p> <p>Q&A</p> <p>Using Molecular Cyst Fluid Analysis For Risk Stratification In Hereditary Pancreatic Cancer Surveillance, Aatur Singhi</p> <p>Q&A</p> <p>How Do Different Endoscopic Techniques Affect Colonoscopy Outcomes?, Pooja Dharwadker</p> <p>Q&A</p>
17:00 - 18:00	<p>Session X: Jeopardy Supported by Ambry Genetics Moderators: Mike Hall & Kimberly Hilfrank</p>
18:00 - 19:00	Poster Session II



Legend	Scientific Sessions
	Committee Meetings & Social Events
	Abstract
	Sponsored Symposium <i>*All Industry Symposia and Session X: Jeopardy will take place in a separate hall, the Industry Symposium Hall – Regency EF.</i>

SATURDAY, OCTOBER 11	
Time Slot	Plenary Hall - Regency ABC
07:00 - 07:45	Breakfast Symposium Sponsored Biodexa Pharmaceuticals: Phase 3 Trial of eRapa in Familial Adenomatous Polyposis: Connecting Rapamycin Effects on APC-Mutated Colon Organoid Maturation with Clinical Response to Treatment Speaker: Patrick (Pat) Lynch
08:00 - 08:15	Welcome & Housekeeping <i>Beth Dudley Yurkovich, CGA-IGC President</i>
08:15 - 09:00	Session XI: Charis Eng Lecture <i>Moderator: Brandie Leach</i> Introduction, <i>Brandie Leach</i> Charis Eng Lecture: What You Should Know About PTEN, <i>Joanne Ngeow</i> Q&A
09:00 - 10:30	Session XII: Upper GI Management <i>Moderators: Jennifer Weiss & Joshua Melson</i> Spigelman Classification: Is It Time For A Change?, <i>Alessandro Mannucci</i> Q&A Implications Of Metabolic Surgery And Medication In Patients With Hereditary GI Syndromes, <i>Rickesha Wilson</i> Q&A Surgical Management Of Duodenal And Ampullary Lesions, <i>Dominic Sanford</i> Q&A
10:30 - 10:50	AM BREAK
10:50 - 12:15	Session XIII: Population Based Testing <i>Moderators: Julie Moskowitz & Heather Hampel</i> The Current State Of Population Based Genetic Testing, <i>Stephanie Cohen</i> Q&A How We Do It: From Awareness to Action: Improving Access to Hereditary Cancer Genetic Testing through Population Screening in a Community Health System, <i>Allison DePersia & Breanne Prindeville & Yvette Shannon</i> Q&A Introduction Ethical Considerations For The Future Of Population Based Genetic Testing, <i>Julie Harris-Wai</i> Q&A
12:15 - 13:30	LUNCH BREAK
13:30 - 15:00	Presidential Plenary III <i>Moderators: Elana Levinson & Gregory Idos</i> O-011 Somatic And Molecular Alterations In Colorectal Cancer By Birth Cohort, <i>Ophir Gilad</i> O-012 Areas Of Uncertainty In Pancreatic Cancer Surveillance: A Survey Across The International Pancreatic Cancer Early Detection (PRECEDE) Consortium, <i>Anjeli Manam</i> O-013 Causes Of Death Among Individuals With Lynch Syndrome (LS) In The Immunotherapy Era, <i>Asaf Maoz</i> O-014 Unexpectedly Low Cancer Incidence Associated with CDH1 Variants in a Large, Unselected Healthcare Population, <i>Hannah E. Krammes</i> O-015 Beyond Familial Adenomatous Polyposis: Genotype-Phenotype Correlations Discern Germline Versus Somatic APC Whole-Gene Deletions Among 860,000 Tests, <i>Katherine Belshe</i> O-016 Effect Of GLP-1 Receptor Agonist Use On Polyp Burden In Familial Adenomatous Polyposis: A Case Series, <i>Diana Jomaa</i>
15:00 - 16:00	CGA-IGC Business Meeting & Presidential Transition <i>Beth Dudley Yurkovich & Mike Hall & Bryson Katona</i> Post Meeting Wrap Up <i>Elana Levinson</i>

INVITED SPEAKERS



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis



Yvonne Bombard
Unity Health
Canada



John Burn
Newcastle University
United Kingdom



Giulia Martina Cavestro
Vita-Salute San Raffaele
University
Italy



James Church
Columbia University Medical
College
United States



Stephanie Cohen
Ascension St. Vincent
United States



Pooja Dharwadkar
University of California,
San Francisco
United States




Dana Farengo Clark
University of Pennsylvania
United States



Julie Harris-Wai
University of California, San
Francisco
United States



Wendy Kohlmann
Huntsman Cancer Institute
United States



Ying Liu
Memorial Sloan Kettering
Cancer Center
United States



Alessandro Mannucci
Vita-Salute San Raffaele
University
Italy



Asaf Maoz
Dana-Farber Cancer Institute
United States



Ata Moshiri
New York University
United States



Joanne Ngeow
Lee Kong Chian School of
Medicine, Nanyang Technological
University, Singapore



Swati Patel
University of Colorado
Anschutz Medical Center
United States



Rodrigo Oliva Perez
Hospital Alemão Oswaldo Cruz
Brazil



Sara Pirzadeh-Miller
UT Southwestern Medical
Center
United States



Maegan Roberts
The Ohio State University
United States



Dominic Sanford
Washington University
United States



Aatur Singhi
Department of Pathology at
the University of Pittsburgh
Medical Center (UPMC)
United States



Zsafia Stadler
Memorial Sloan Kettering
Cancer Center
United States



Ben White
Fight Colorectal Cancer
United States




Rickesha Wilson
Cleveland Clinic
United States



Charité Ricker
Keck School of Medicine of USC;
Los Angeles General
Medical Center
United States

SPONSORS & EXHIBITORS



2025 CGA-IGC Annual Meeting

October 9-11, 2025
St. Louis

We would like to thank the sponsors and exhibitors below for their invaluable contribution to the 29th CGA-IGC Annual Meeting (CGA-IGC 2025)

PLATINUM SPONSORS



GOLD SPONSORS


SPONSORS & EXHIBITORS



The James



SPONSORED INDUSTRY SESSIONS



2025 CGA-IGC
Annual Meeting

October 9-11, 2025
St. Louis

EXACT SCIENCES INDUSTRY SYMPOSIUM

Date : THURSDAY / OCTOBER 9
Time : 07:00 - 07:45
Title : Cologuard and Colorectal Cancer Detection in Lynch Syndrome--An Introduction to the CORAL Study
Moderator : Brandie Leach, MS, CGC
Speakers : Bryson Katona, MD, PhD
Jordan J. Karlitz, MD, FACP, AGAF

The logo for Exact Sciences, featuring the word "EXACT" in a stylized font with a purple 'X' and "SCIENCES" in a bold, black, sans-serif font.

NATERA INDUSTRY SYMPOSIUM

Date : THURSDAY / OCTOBER 9
Time : 12:20 - 13:20
Title : Bridging the Gap: Driving hereditary testing uptake using integrated somatic-germline insights
Speakers : Abigail Ward, MS, CGC
Asaf Maoz, MD

The logos for Natera and Empower. Natera is represented by a blue and green circular icon followed by the word "natera" in lowercase. Empower is represented by the word "Empower" in a bold font with "Hereditary cancer test" in a smaller font below it.

AMBRY GENETICS INDUSTRY SYMPOSIUM

Date : FRIDAY / OCTOBER 10
Time : 07:00 - 07:45
Title : GI Classifi-ed: Our Comprehensive and Adaptive Approach to Genomic Results Interpretation
Speakers : Holly LaDuca, MS, CGC
Jeni Herrera-Mullar, MGC, LCGC, DMA
Tina Pesaran, MA, MS, CGC


The logo for Ambry Genetics, featuring a blue and white wave-like icon followed by the text "Ambry Genetics" and "A TEMPUS COMPANY" below it.

IMMUNOVIA INDUSTRY SYMPOSIUM

Date : FRIDAY / OCTOBER 10
Time : 12:20 - 13:20
Title : Controversies in Pancreatic Cancer Surveillance Guidelines and the Potential Role for Blood Based Biomarker Testing
Moderator : Jeff Borcharding
Speaker : Bryson Katona, MD

The logo for Immunovia, featuring a circular cluster of purple dots of varying sizes followed by the word "immunovia" in a lowercase, sans-serif font.

SPONSORED INDUSTRY SESSIONS



2025 CGA-IGC
Annual Meeting

October 9-11, 2025
St. Louis

JEOPARDY SPONSORED BY AMBRY GENETICS

Date : FRIDAY / OCTOBER 10

Time : 17:00 - 18:00

Moderators : Mike Hall & Kim Hilfrank

Teams : **Hereditary or Not, Here We Come**

Carol Burke

Eve Karloski

Paul Wise

Guardians of the Genome

Dana Zakalik

Maureen Mork

Randall Brand

Uninhibited Checkpoints

Anu Chittenden

Katharine Germansky

Matthew Yurgelun

 **Ambry Genetics**[®]

A TEMPUS COMPANY

BIODEXA PHARMACEUTICALS INDUSTRY SYMPOSIUM


Date : SATURDAY / OCTOBER 11

Time : 07:00 - 07:45

Title : Phase 3 Trial of eRapa in Familial Adenomatous Polyposis: Connecting Rapamycin Effects on APC-Mutated Colon Organoid Maturation with Clinical Response to Treatment

Speaker : Patrick (Pat) Lynch

 **biodexa**
pharmaceuticals



AliveandKick'n

AliveandKick'n has a mission to improve the lives of individuals and families affected by Lynch syndrome and associated cancers through research, education and screening.



Ambry Genetics

Ambry Genetics, a wholly owned subsidiary of Tempus, translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing and aims to improve health by understanding the relationship between genetics and disease. Over its 25-year history, Ambry has remained committed to empowering patients to make informed healthcare decisions based on their genetic data.



Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company's lead development program, eRapa, is undergoing a phase 3 registration study in Familial Adenomatous Polyposis. eRapa is a proprietary oral tablet formulation of rapamycin (sirolimus), an mTOR inhibitor. mTOR is known to have a role in regulation of cellular metabolism, growth and proliferation and is activated during tumorigenesis. eRapa is designed to improve the bioavailability of rapamycin.


The company is also working on treatments for type 1 diabetes and primary and metastatic cancers of the brain.



Caris Life Sciences®

Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (DNA, RNA and proteins) and the application of AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. To learn more, please visit [CarisLifeSciences.com](https://www.CarisLifeSciences.com).





CCARE



ClearNote Health, Inc. (CNH)

Address : 10578 Science Center Dr. Suite 210 San Diego, CA 92121
Phone : 833-258-7827
Web : www.clearnotehealth.com




ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives. Utilizing a standard blood draw, our proprietary epigenomic platform combines biology and artificial intelligence to provide a more comprehensive view of biology to identify DNA-based changes in biology as cancer develops. With our focus on high-mortality cancer detection in high-risk patients, ClearNote Health is changing the patient care paradigm by offering clinicians and their patients a better way to identify cancers at a more treatable stage.

ConnectMyVariant

Address : info@connectmyvariant.org
Web : <https://connectmyvariant.org/>



ConnectMyVariant is an educational organization that supports patients with family outreach and cascade testing. We provide unique value by leveraging family connections to help people identify other at-risk relatives. We bring people with the same genetic risk together to share experiences, find common ancestors, and help each other get the best medical care. ConnectMyVariant also works to increase awareness of hereditary disease and the benefits of family outreach among physicians and other health care providers who provide primary and prevention care.



Dana-Farber Cancer Institute

Web : <https://www.dana-farber.org/>

The Lynch Syndrome Center at Dana-Farber Cancer Institute is a unique multi-disciplinary center that specializes in coordinating all aspects of care for people with Lynch syndrome.

Launched in 2019, our Center features clinical experts from various specialties with particular expertise in Lynch syndrome, provides personalized longitudinal care and support for individuals and families with Lynch syndrome while utilizing state-of-the-art diagnostic tools and conducts cutting edge research on Lynch syndrome and translate research breakthroughs to leading-edge prevention and treatment methods. We offer genetic testing and counseling, coordinated care from expert specialists, a community for patients and provider education and events.



Lynch Syndrome Center

Exact Sciences

Web : <https://www.exactsciences.com/>

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.


The logo for Exact Sciences, featuring the word "EXACT" in a large, bold, black font with a stylized "X" that has a blue and orange gradient, and the word "SCIENCES" in a smaller, bold, black font below it.

Fight CRC

Web : <https://fightcolorectalcaner.org/>

For patients, caregivers, and families affected by colorectal cancer, Fight CRC is the leading empowerment and advocacy organization working to provide hope and healing through a supportive, informed community. Fight CRC relentlessly pursues the most promising research endeavors and takes bold action to impact policy change.

The logo for Fight CRC, featuring the word "FIGHT" in a large, bold, orange font with a blue star above the letter "I", and the words "COLORECTAL CANCER" in a smaller, blue font below it.



Immunovia

Address : 800 Capitola Dr. Suite 1, Durham, NC 27713
Phone : (833)593-9522
Web : <https://immunovia.com/>



Immunovia has developed a blood test to assess biomarkers that together detect early-stage pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals.

For patients with familial or genetic risk, annual surveillance with imaging such as MRI and/or EUS is recommended. Clinical guidelines state the need for additional surveillance methodologies, namely blood tests.

PancreaSure™, Immunovia's new protein-based serum biomarker test for early-stage detection of PDAC, meets this need. Immunovia's clinical validation study, CLARITI (n=1,066), shows PancreaSure has high accuracy with 78% sensitivity and 94% specificity in detecting Stage I and Stage II PDAC. Immunovia's second clinical validation study, VERIFI (n=385), reports similar results.

Invitae

Web : <https://www.invitae.com/>



Invitae is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

To learn more, visit [invitae.com](https://www.invitae.com/) and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae

The Jacqueline Rush Foundation


Web : <https://www.jrushfoundation.org/>



The Jacqueline Rush Foundation is a Lynch Syndrome Cancer Foundation with a mission to save lives by improving the public and medical community awareness of Lynch Syndrome and to raise funds for Lynch Syndrome research.

We also provide support, education and resources to those with Lynch Syndrome and their families. We are building a community so those with Lynch Syndrome are never alone.

It shouldn't take a cancer diagnosis to find out you have inherited Lynch Syndrome!. The key to preventing cancer or catching it early when it can be cured is knowing what's in your genes and what your cancer risks are.



jscreen®

Web : jscreen.org

jscreen® is a national non-profit public health initiative offering accessible genetic testing and personalized support. We provide education, testing, and high-touch care navigation to help individuals understand their risk for hereditary cancers and genetic conditions. Our medical-grade, at-home kits and expert genetic counseling empower people to make informed decisions about their health and family planning. jscreen partners with healthcare providers, universities, and communities to promote awareness and increase access to preventive genetic testing across the U.S.



King Center for Lynch Syndrome at Penn Medicine's Abramson Cancer Center

Address : 3400 Civic Center Boulevard, Philadelphia, PA 19104

Web : www.med.upenn.edu/lynchsyndromesymposium

The King Center for Lynch Syndrome at Penn Medicine's Abramson Cancer Center is dedicated to the clinical care of individuals with Lynch syndrome as well as to advancing education, outreach, and research in Lynch syndrome. The King Center's Annual Symposium provides an opportunity to hear directly from a multi-disciplinary team of experts at the forefront of ground-breaking research and discovery, while the program's newsletter and webinars share year-round updates on clinical and research advancements in the field.




Lynch Syndrome Awareness

Web : <https://lynchsindromeawareness.com/>

Lynch Syndrome Awareness and Education is a national nonprofit dedicated to increasing understanding of Lynch Syndrome within both the general public and the medical community. Many remain unfamiliar with this hereditary genetic condition, leaving countless families at risk. We believe that by promoting education, encouraging genetic testing, and providing clear, accessible resources, we can empower individuals to take proactive steps for their health. Through awareness campaigns, advocacy, and collaboration with healthcare professionals, our mission is simple yet vital: to save lives by turning knowledge into action.





Lynsight

Address : Arabiankatu 12, 00560 Helsinki, Finland
Phone : +358 40 660 2622
Web : <https://lynsightlabs.com/>



Lynsight is a leading organisation in Lynch syndrome diagnostics dedicated to reducing cancer mortality through its precise and innovative testing method for inherited MMR deficiency, DiagMMR. Our mission is to empower families and healthcare professionals to make better-informed decisions for cancer prevention. With over a decade of research at the forefront of Lynch syndrome, Lynsight originated from work conducted at the University of Helsinki and continues to pursue comprehensive testing for all potential Lynch syndrome cases. We invite you to visit our booth to discuss collaborative opportunities to expand access to DiagMMR testing within the United States.

Myriad Oncology

Myriad Oncology, a business unit of genetic and tumor genomic testing and precision medicine leader Myriad Genetics, provides an expanding portfolio of advanced genetic and tumor genomic testing solutions, meeting the specific needs of clinicians and their oncology patients.

Myriad Oncology products support every step of the patient care journey—spanning previvorship, screening, treatment, and survivorship. Bolstered by unparalleled services and patient education, Myriad Oncology is dedicated to empowering clinicians and their patients with confidence and clarity to navigate the unique challenges of each patient's cancer journey.



Natera


Hereditary cancer testing, made accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis.

Empower screens for genes associated with increased risk for common hereditary cancers. Our Empower multi-cancer panels include commonly screened-for genes associated with 12+ types of cancer.

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives..





Pancreatic Cancer Action Network (PanCAN)

Address : 2101 Rosecrans Ave, Suite 3200 El Segundo, CA 90245
Phone : 877-272-6226
Web : www.pancan.org

The logo for the Pancreatic Cancer Action Network, featuring the text "PANCREATIC CANCER ACTION NETWORK" in white capital letters on a dark purple square background.

The Pancreatic Cancer Action Network (PanCAN) is the leading organization dedicated to advancing progress against pancreatic cancer. We unite the pancreatic cancer community and push every boundary to create a world where survival is the norm not the exception. PanCAN empowers patients and caregivers with the resources and knowledge they need to advocate for the care they deserve. We are pioneering the advancement of an early detection strategy for pancreatic cancer and revolutionizing the development of advanced and personalized treatments; and we are building and mobilizing the pancreatic cancer field to ensure better outcomes for all those who face pancreatic cancer today and all those who will fight this disease tomorrow.

Project DNA

Address : 23 Upper Ragsdale Drive, Suite 200, Monterey, CA 93940
Phone : 831-375-3577
Web : www.projectdna.org



Project DNA is a nonprofit 501 C3 Corporation whose mission is to create systematic programs to identify patients at risk for hereditary cancer syndromes every time they touch the healthcare setting. Hereditary cancer syndromes are not rare. 1 out of every 25-50 people in the United States have a hereditary cancer syndrome. By identifying these people, we can frequently prevent them from getting cancer or diagnose cancer at a curable stage. We cannot change their family history, but we can change their family's future. For more information, please visit www.projectdna.org.

Siteman Cancer Center

Siteman Cancer Center is one of only a few cancer centers to receive the highest rating of the National Cancer Institute (NCI) – “exceptional.” Comprising the cancer research, prevention and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Siteman treats adults at six locations, including a new outpatient facility and an inpatient hospital on the Washington University Medical Campus, and partners with St. Louis Children's Hospital in the treatment of pediatric patients at Siteman Kids. All locations offer patient-focused, multidisciplinary care driven by scientific breakthroughs and powered by Washington University Physicians.





Tempus

WEB : www.tempus.com

Tempus is a technology company leading the adoption of AI to advance precision medicine and patient care.

The logo for Tempus, featuring the word "TEMPUS" in a bold, black, sans-serif font, enclosed within a thin purple rectangular border.

The Ohio State University Comprehensive Cancer Center

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is the only cancer program in the United States that features a National Cancer Institute designation as a comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital. Since 1976, The James has conducted NCI-funded phase I and II clinical trials and has been ranked among the top cancer hospitals by U.S. News & World Report for 26 years. The James prides itself on Magnet® recognition, over 350 inpatient beds and 1.1 million square feet, plus outpatient centers, making it the third-largest cancer hospital in the nation.

The James



UPMC

Web : <https://www.upmc.com/>

UPMC is a leading health care provider and academic medical center headquartered in Pittsburgh, dedicated to advancing medicine through innovation, research, and education. In partnership with the University of Pittsburgh, UPMC delivers expert, compassionate care. The UPMC Hereditary GI Tumor Program offers comprehensive, multidisciplinary evaluation and management for individuals and families with inherited gastrointestinal cancer risk. Patients receive personalized care from genetic counselors and gastroenterologists, including risk assessment, genetic testing, and prevention strategies. The program serves those with early-onset cancers, family histories, polyposis syndromes, or known genetic mutations associated with GI cancer predisposition.

The logo for UPMC, featuring the letters "UPMC" in a large, bold, purple, sans-serif font, with the tagline "LIFE CHANGING MEDICINE" in a smaller, black, sans-serif font below it, all enclosed within a thin purple rectangular border.



A PATH FORWARD

FOR FAMILIES WITH HEREDITARY CANCER



Lynch syndrome is one of the most common causes of hereditary cancers but difficult to diagnose. Lynsight offers a new way to test for Lynch syndrome, so healthcare providers can focus on the path instead of the problem. Founded in Helsinki in 2013, we've been on the forefront of Lynch syndrome research since the 1990s and our team of experts is committed to pushing the boundaries of scientific discovery. We're leading the way toward a future where Lynch syndrome testing is more accessible and accurate.

Find out more at [LYNSIGHTLABS.COM](https://lynslightlabs.com)

The Gateway Arch

DESIGNED BY FINNISH ARCHITECT

Eero Saarinen

Setting the Standard for Genetic Testing

Supporting you with exceptional service and comprehensive test offerings.


ambrygen.com





Changing lives, **together**

Exact Sciences is changing the way we think about detecting cancer and providing treatment insights. As a leader in screening and precision oncology, we are committed to providing earlier answers and life-changing treatment guidance.

Hereditary risk	Screening & surveillance	Treatment guidance	Molecular residual disease (MRD) & recurrence monitoring	Therapy selection
riskguard [®] Hereditary Cancer Test	 cologuard [®] cologuard plus [™]	oncotype dx [®] Breast Recurrence Score [®] Breast DCIS Score [®] Colon Recurrence Score [®]	oncodetect [™] Molecular Residual Disease	oncoExTra [®] Tissue Genomic Profiling
	oncoguard [®] liver cancerguard [™]	riskguard [®] Hereditary Cancer Test		oncoliquid [™] * riskguard [®] Hereditary Cancer Test

*Test in development, not commercially available.

EXACT
SCIENCES[®]

Want to learn more?
ExactSciences.com

Want to order a test?
provider.exactsciences.com
riskguard@exactsciences.com

Have a question?
866-662-6897

Cologuard and Cologuard Plus are intended to screen adults 45 and older at average risk for colorectal cancer. Rx only. See risk information at Cologuard.com. Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Colon Recurrence Score, Oncodetect, and OncoExTra are trademarks of Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation. Exact Sciences, Cologuard, Cologuard Plus, Riskguard, Cancerguard, and Oncoguard are trademarks of Exact Sciences Corporation.

© 2025 Exact Sciences Corporation. All rights reserved. M-US-CAG-00484




Empower™
Hereditary cancer test

Signatera™
Residual disease test (MRD)

Hereditary Cancer Alert Program


Proactively identify Signatera™ patients for germline testing



Closing the gap:

Testing of at-risk patients increased by up to 2x in cancer centers

[Learn more here](#)



Choose Empower™ for customizable and accessible hereditary cancer testing:

- Pre-curated panels and easy-to-use functionality for customization options up to 192 genes
- RNA analysis for variant resolution with no additional sample or cost required
- Same-size panel Family Testing Program (FTP) at no additional cost
- Accessible and transparent pricing, pricing cap and cash pay options

**The leader
in molecular
diagnostics**



20+ years
in operation



300+
peer-reviewed
publications

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2025 Natera, Inc. All Rights Reserved. EMP_AD_CGAIGC25_FinalProgBook_20250825_NAT-8022833



2026 CGA-IGC Annual Meeting

The Collaborative
Group of the
Americas on
Inherited
Gastrointestinal
Cancer

November 2-4, 2026 / Denver

**SAVE
THE DATE**



www.cgaigcmeeting.org

#CGAIGC26



**kenes
group**

Annual Meeting
Organizing Secretariat, PCO:
Kenes Group, Office: M+
Contact: lvulkan@kenes.com